title: The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
abstract: OBJECTIVE
  This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control group that continued receiving haloperidol decanoate depot.
  
  
  METHODS
  This study was a 24-week, non-randomized, non-double blind, open-label trial. The subjects' clinical symptoms were assessed using the Positive and Negative Syndrome Scale, and their cognitive function was assessed using the Wisconsin Card Sorting Test: Keio Version to assess executive function and the St. Marianna University School of Medicine's Computerized Memory Test to assess memory and concentration at 0 and 24 weeks.
  
  
  RESULTS
  The mean change from baseline in the number of categories achieved at the second stage of the Wisconsin Card Sorting Test: Keio Version was significantly greater in the RLAI group than in the control group. The mean changes from baseline in the individual St. Marianna University School of Medicine's Computerized Memory Tests were significantly greater in the RLAI group than in the control group. The RLAI group needed a lower dosage of biperiden compared with the control group, even though they had similar risperidone-equivalent daily dosages.
  
  
  CONCLUSIONS
  The results of this study suggest the possibility that switching from haloperidol decanoate depot to RLAI may improve cognitive function including memory, executive function, motor processing function, and attention.
authors.affiliation: Department of Psychiatry, Tanzawa Hospital, Hadano, Japan. suzuhide@red.livedoor.com
authors.forename: Hidenobu
authors.initials: H
authors.lastname: Suzuki
authors.forename: Keishi
authors.initials: K
authors.lastname: Gen
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology; D003692:Delayed-Action Preparations; D003936:Diagnosis, Computer-Assisted; D056344:Executive Function / Q000187:drug effects; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; C033563:haloperidol decanoate; D006220:Haloperidol; D018967:Risperidone